聚焦股权投资行业人物、事件、数据、研究、政策解读，提供专业视角和深度洞见 | 创投圈有趣的灵魂 以下文章来源于东四十条资本 ，作者刘燕秋 东四十条资本 . 将投中网设为"星标⭐"，第一时间收获最新推送 0营收的中药公司，搭上"脑机接口"起飞。 作者丨 刘燕秋 来源丨 东四十条资本 这家神奇的公司还得从创始人说起。根据公司官网信息，区逸基，Regencell创始人兼首席执行官，毕业于加州大学伯克利分 校哈斯商学院。获得学士学位后，他投身投资银行领域，先后就职于德意志银行和巴林银行。 在职业生涯中，区逸基成果斐然，完成超 40 亿美元交易，荣获多项重要并购奖项。他的代表交易包括代表第一太平有限公 司，以7.5亿美元收购菲律宾长途电话公司、6.5亿美元收购Indofood，以及完成 Hagemeyer 40% 股权18亿美元的增发 。 此外，他还是房地产、科技和生物科技领域的活跃投资者。 然而这位青年才俊的成长之路并非一帆风顺。童年时期，区逸基因患有注意力缺陷多动障碍（ADHD）和自闭症（ASD）。受 病症影响，他脾气暴躁，在学校备受孤立，成绩也不理想，高中时成绩甚至排倒数。为完成学业，他每天都需花费远超常人的 时 ...

Core Viewpoint - Pianzaihuang (600436.SH) has topped the "Hurun Brand List" for five consecutive years but is facing significant challenges, including a slowdown in revenue and profit growth in 2024, attributed to rising raw material costs and a failed pricing strategy [1][2]. Financial Performance - In 2024, Pianzaihuang achieved revenue of approximately 10.788 billion yuan, a year-on-year increase of 7.25%, and a net profit of 2.977 billion yuan, up 6.42% [2]. - The revenue growth rate for 2024 is the lowest since 2016, with a notable decline in Q4, where both revenue and net profit decreased [2][3]. - Q4 revenue was 2.338 billion yuan, marking a year-on-year decline of 4.92%, while net profit fell by 26.07% [2][3]. Cost Pressures - Rising prices of key raw materials have significantly impacted profit margins, with the price of natural cow bile increasing from 650,000 yuan/kg in January 2023 to 1.65 million yuan/kg by January 2025 [4][5]. - Pianzaihuang's inventory increased by 47.01% year-on-year to approximately 4.987 billion yuan, with raw material inventory growing by about 60% [5]. Pricing Strategy - In May 2023, Pianzaihuang raised the price of its main product, Pianzaihuang pills, by 28.8%, but this led to a decline in sales volume in 2024 [6][7]. - The revenue from the pharmaceutical manufacturing segment was approximately 5.663 billion yuan in 2024, a growth rate lower than the previous year [6][7]. Business Segments - The liver disease medication segment generated about 5.31 billion yuan in revenue, growing 18.98%, while the cardiovascular medication segment saw a revenue increase of only 7.03% [7]. - The cosmetics business, viewed as a secondary growth driver, accounted for less than 10% of total revenue and has shown stagnant growth over the past four years [9]. Regional Performance - Revenue growth varied by region, with the Northeast and North China regions experiencing declines in revenue and gross margin [8]. - The East China region, a key market for Pianzaihuang, saw only a 0.79% increase in revenue, the slowest growth among domestic regions [8].

Group 1 - The core viewpoint of the news is that Guangxi is actively promoting health consumption through various measures, including subsidies for aging-related medical products and reforms to facilitate the import of traditional Chinese medicine (TCM) products [1][2] Group 2 - In promoting medical consumption, Guangxi has included aging-related products in the subsidy program, offering a maximum subsidy of 1,000 yuan per product category, resulting in 6,054 products distributed and sales amounting to 8.64 million yuan, with subsidies totaling 2.25 million yuan [1] - The import of TCM products has been facilitated by reforms that allow certain products to be imported without the need for a drug import clearance, leading to a significant increase in the import value of TCM products, which reached 4,306.3 million USD in the first four months of 2025, a 4.3-fold increase compared to the previous year [1] Group 3 - Guangxi is supporting the construction of TCM service export bases and has allocated 1 million yuan annually for three years to promote international cooperation and trade in TCM products, resulting in an export volume of 5,386.5 tons and an export value of 1.26 billion yuan in the first four months of 2025 [2] - The import of TCM products has also seen a significant increase, with 12,400 tons imported, marking a 555.6% year-on-year growth, with an import value of approximately 4,032.3 million yuan [2] Group 4 - Future initiatives include promoting "Internet + drug distribution" and supporting retail drug companies to collaborate with online platforms, as well as implementing health consumption vouchers and discount activities to enhance the quality of health goods and services [2]

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-37 东阿阿胶股份有限公司 第一期限制性股票激励计划（草案二次修订稿）及其摘要的议案》及相关议案， 并与股东大会决议同步披露了《关于第一期限制性股票激励计划内幕信息知情人 及激励对象买卖公司股票情况的自查报告》。 事会第八次会议，审议通过了《关于调整第一期限制性股票激励计划相关事项的 议案》 根据东阿阿胶股份有限公司（以下简称"公司"）2024 年年度股东大会的授 权，公司于 2025 年 6 月 18 日召开第十一届董事会第九次会议和第十一届监事会 第八次会议，审议通过了《关于调整第一期限制性股票激励计划相关事项的议案》。 现将有关事项说明如下： 一、已履行的相关审批程序和信息披露情况 《关于向第一期限制性股票激励计划激励对象首次授予限制性股票的议案》。 公司监事会对本次激励计划首次授予激励对象名单进行核实并发表了核查意见。 事会第十三次会议，审议通过了《关于第一期限制性股票激励计划（草案）及其 摘要的议案》。 事会第五次会议，审议通过了《关于第一期限制性股票激励计划（草案修订稿） 及其摘要的议案》。 公告》。 事会第七次会议，审议通过了《关于 ...

Core Points - The document outlines the governance structure and operational guidelines for Dong'e Ejiao Co., Ltd, focusing on the role and responsibilities of the President [1][2][3] - It specifies the qualifications required for the President and the procedures for their appointment and dismissal [1][2][3] - The President is responsible for the daily management of the company and must report to the Board of Directors and the Supervisory Board [3][7] Section Summaries General Provisions - The company aims to enhance its corporate governance structure in accordance with relevant laws and regulations [1] - The President is appointed by the Board and serves a term of three years, with the possibility of reappointment [1] Qualifications and Appointment Procedures - The President must possess loyalty, innovation, management skills, and relevant experience [1] - Specific disqualifications for the President include criminal convictions and financial irresponsibility [1] Powers of the President - The President has the authority to act as the legal representative of the company and is responsible for implementing Board decisions [3][4] - The President can propose financial budgets, profit distribution plans, and manage asset transactions within specified limits [3][4][5] Reporting System - The President is required to report to the Board and Supervisory Board at least biannually on various operational aspects [7] - Reports must include updates on development plans, operational issues, and significant contracts [7] Meeting Procedures - Major operational decisions must be discussed in meetings led by the President, ensuring informed decision-making [8][9] - Meeting minutes must be documented and distributed to relevant parties for implementation [8][9] Compensation and Evaluation - The President's compensation is linked to the company's annual performance and requires Board approval [16][17] - Annual evaluations of the President and senior management are conducted based on performance indicators [17] Obligations of the President - The President has a duty of diligence and loyalty to the company, including confidentiality and non-competition obligations [19][20] - Any breach of these obligations may result in legal consequences for the President [21][22] Miscellaneous Provisions - The document serves as an auxiliary guideline to the company's articles of association and is subject to interpretation by the Board [11][12]

Group 1 - The supervisory board meeting was held on June 15, 2025, and the notice was sent via email [1] - The supervisory board approved the adjustment of the first phase of the restricted stock incentive plan, confirming it aligns with relevant regulations and does not harm shareholder interests [1] - The adjusted incentive objects meet the conditions set forth in the management measures and the incentive plan [1] Group 2 - The supervisory board agreed that the initial grant date of June 18, 2025, complies with the management measures and the incentive plan [2] - A total of 984,043 restricted shares will be granted to 176 eligible incentive objects at a price of 35.95 yuan per share [2] - The approval vote was unanimous with 5 votes in favor, 0 against, and 0 abstentions [2]

Core Viewpoint - The 9th China-South Asia Expo aims to enhance regional cooperation and economic development through open collaboration, attracting businesses from South Asia and Southeast Asia to Kunming [1][2]. Trade and Economic Cooperation - The trade volume between China and South Asian countries is projected to approach $200 billion in 2024, doubling over the past decade with an average annual growth rate of approximately 6.3% [1][2]. - South Asian products such as cashmere, lapis lazuli, and spices are gaining popularity among Chinese consumers, presenting significant market opportunities [1]. - Investment cooperation is also on the rise, with projects like the China-Pakistan Economic Corridor and various energy and infrastructure projects in Sri Lanka, Bangladesh, and Nepal contributing to regional economic growth [2]. Policy and Institutional Support - The China-Maldives Free Trade Agreement has come into effect, and negotiations for an investment agreement with Bangladesh are underway, aimed at facilitating trade and investment [2]. - China is providing zero-tariff treatment for 100% of products from several least developed South Asian countries, enhancing their export capabilities to China [2]. Regional Connectivity and Development - Yunnan province is positioned as a key hub connecting China with South Asia and Southeast Asia, leveraging its geographical advantages to promote trade and logistics [3]. - The province is actively implementing measures to enhance regional connectivity, including the construction of the China-Laos Railway and various trade facilitation initiatives [3]. Global Economic Context - The backdrop of rising protectionism and unilateralism in global trade necessitates stronger cooperation among developing countries, including those in South Asia, to enhance economic resilience [3][4]. - China is committed to opposing protectionism and fostering an open economic environment through various national and international trade exhibitions [4]. Collaborative Future - The expo serves as a platform for countries to unite in collaboration and development, aiming to create new growth points and drive regional prosperity [5].

京东方Ａ公告称，彩虹股份拟出售所持咸阳彩虹光电科技有限公司（简称"彩虹光电"）30%股权。公 司根据公司发展战略，为紧抓产业格局整合演进机遇，进一步提升公司竞争力，拟收购上述30%股 权。本次交易挂牌底价为48.49亿元。 2连板东信和平：公司积极布局区块链、数字钱包等领域研发与应用，部分项目或产品应用场景等存 在较大不确定性 东信和平发布异动公告称，公司股票在连续2个交易日内日收盘价格涨幅偏离值累计超过20%，属于 股票交易异常波动的情况。公司关注到近期市场对数字人民币、稳定币关注度较高，近年来公司持续 聚焦前沿技术，积极布局区块链、隐私计算、数字钱包等领域的研发与应用，但面临新技术研发及商 业应用不达预期的风险，部分项目或产品的应用场景、市场规模尚存在较大不确定性，公司提醒广大 投资者审慎决策、理性投资。 2025.07. 17 6月17日晚间，沪深两市多家上市公司发布公告，以下是第一财经对一些重要公告的汇总，供投资者 参考。 【品大事】 京东方A：拟收购彩虹光电30%股权 大秦铁路：聘任张竑毅为总经理 大秦铁路公告，因达到法定退休年龄，公司董事会决定解聘韩洪臣总经理职务。经董事长陆勇提名， 董事会提名委 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-048 甘肃陇神戎发药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 一、会议召开和出席情况 （一）会议召开情况 （1）现场会议召开时间：2025 年 6 月 17 日下午 14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 互联网投票系统进行网络投票的时间为2025年6月17日9:15—15:00期间的任意 时间。 部门规章、规范性文件和《公司章程》的规定。 （二）会议出席情况 出席本次股东会现场会议和网络投票的股东及股东授权委托代表共 192 人， 代表股份 118,310,230 股，占公司总股本的 39.0019％。 二、议案审议表决情况 本次会议以现场投票和网络投票相结合的方式对以下议案进行了表决，表决 结果如下： 其中：出席现场会议的股东及股东授权委托代表共 4 人，代表股份数 议的股东共 188 人，代表股份数 4,250,920 股，占公司有表决权股份总数的 出席本次股东会现场会议和网络投票的中小股东及股东授权委托代表共 18 ...

新华财经上海6月17日电（记者魏雨田）今年以来，医药板块延续结构性行情热度，其中创新药赛道表 现尤为亮眼。财通基金医药基金经理骆莹的投资框架以"攻守平衡"为锚，在投资布局中构建"低估值底 仓 + 进攻性仓位"的双轮驱动策略。 针对创新药板块的持续狂热，骆莹在接受记者采访时表示，目前市场对创新药的想象空间有过度透支的 风险，虽具体触发时点难以预判，但风险规避或是更稳妥的策略。展望后市，骆莹持续看好中药与医药 设备板块的发展潜力，其中保健滋补类产品及心脑血管领域为其目前重点关注方向。 透支未来存估值风险 拥有上海交通大学生物医学工程本科与安泰金融硕士复合背景的骆莹，在医药投资领域已深耕十余年。 从卖方医药研究员，再到买方医药研究员，她完整经历了行业多轮周期更迭。丰富的职业经历塑造了她 独特的投资框架。 骆莹投资框架的核心逻辑是"估值是投资的锚"。她认为，透支未来增长的估值难以持续。当资产价格脱 离合理价值区间，离场时机将难以判断。因此，她始终坚持一个原则：一旦价格触及内在价值测算边 界，就果断退出。这种对估值的严谨把控，成为她投资决策的重要依据。 "这轮行情本质是PD-1类产品专利到期周期下，下一代免疫疗法崛起引 ...